The transport of antiepileptic drugs by P-glycoprotein

Advanced Drug Delivery Reviews

Volumn 64, Issue 10, 2012, Pages 930-942

  Zhang, Chunbo ^a   Kwan, Patrick ^b,c,d   Zuo, Zhong ^a   Baum, Larry ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Antiepileptic drugs; Blood brain barrier; Drug resistance; Epilepsy; P glycoprotein; Structure activity relationship

Indexed keywords

ANTIEPILEPTIC DRUGS; BLOOD-BRAIN BARRIER; DRUG RESISTANCE; EPILEPSY; P-GLYCOPROTEIN; STRUCTURE ACTIVITY RELATIONSHIPS;

BLOOD; ENDOTHELIAL CELLS; GLYCOPROTEINS; SUBSTRATES;

DRUG INTERACTIONS;

2,4 DINITROPHENOL; ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CARBON 11; CYCLOSPORIN A; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GLYCOPROTEIN P INHIBITOR; KETOCONAZOLE; LAMOTRIGINE; LICARBAZEPINE; MULTIDRUG RESISTANCE PROTEIN 1; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROBENECID; SODIUM CYANIDE; TARIQUIDAR; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VALSPODAR; VERAPAMIL; VIGABATRIN; ZONISAMIDE;

BLOOD BRAIN BARRIER; BRAIN TISSUE; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TRANSPORT; ENDOTHELIUM CELL; EPILEPSY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROLOGIC DISEASE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; TEMPORAL LOBE EPILEPSY;

ANIMALS; ANTICONVULSANTS; EPILEPSY; HUMANS; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860706745     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.12.003     Document Type: Review

References (133)

1. Aiken S.P., Brown W.M. Treatment of epilepsy: existing therapies and future developments. Front. Biosci. 2000, 5:E124-E152.
2. Hauser W.A., Annegers J.F., Kurland L.T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993, 34:453-468.
3. Shorvon S.D. Epidemiology, classification, natural history, and genetics of epilepsy. Lancet 1990, 336:93-96.
4. Everitt A.D., Sander J.W. Classification of the epilepsies: time for a change? A critical review of the International Classification of the Epilepsies and Epileptic Syndromes (ICEES) and its usefulness in clinical practice and epidemiological studies of epilepsy. Eur. Neurol. 1999, 42:1-10.
5. Berg A.T., Berkovic S.F., Brodie M.J., Buchhalter J., Cross J.H., van Emde Boas W., Engel J., French J., Glauser T.A., Mathern G.W., Moshe S.L., Nordli D., Plouin P., Scheffer I.E. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51:676-685.
6. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 2000, 9:464-468.
7. Regesta G., Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999, 34:109-122.
8. Kwan P., Arzimanoglou A., Berg A.T., Brodie M.J., Allen Hauser W., Mathern G., Moshe S.L., Perucca E., Wiebe S., French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
9. Weiss J., Kerpen C.J., Lindenmaier H., Dormann S.M., Haefeli W.E. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J. Pharmacol. Exp. Ther. 2003, 307:262-267.
10. Ballabh P., Braun A., Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 2004, 16:1-13.
11. Pardridge W.M. Blood-brain barrier delivery. Drug Discov. Today 2007, 12:54-61.
12. Ghose A.K., Viswanadhan V.N., Wendoloski J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1999, 1:55-68.
13. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 2005, 6:591-602.
14. Loscher W., Sills G.J. Drug resistance in epilepsy: why is a simple explanation not enough?. Epilepsia 2007, 48:2370-2372.
15. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455:152-162.
16. Gottesman M.M., Pastan I. The multidrug transporter, a double-edged sword. J. Biol. Chem. 1988, 263:12163-12166.
17. Hennessy M., Spiers J.P. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol. Res. 2007, 55:1-15.
18. Mizuno N., Niwa T., Yotsumoto Y., Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 2003, 55:425-461.
19. Kemper E.M., van Zandbergen A.E., Cleypool C., Mos H.A., Boogerd W., Beijnen J.H., van Tellingen O. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res. 2003, 9:2849-2855.
20. Kemper E.M., Verheij M., Boogerd W., Beijnen J.H., van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur. J. Cancer 2004, 40:1269-1274.
21. Fellner S., Bauer B., Miller D.S., Schaffrik M., Fankhanel M., Spruss T., Bernhardt G., Graeff C., Farber L., Gschaidmeier H., Buschauer A., Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 2002, 110:1309-1318.
22. Loscher W. Drug transporters in the epileptic brain. Epilepsia 2007, 48(Suppl. 1):8-13.
23. Aronica E., Gorter J.A., Jansen G.H., van Veelen C.W., van Rijen P.C., Leenstra S., Ramkema M., Scheffer G.L., Scheper R.J., Troost D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003, 118:417-429.
24. Aronica E., Gorter J.A., Ramkema M., Redeker S., Ozbas-Gerceker F., van Vliet E.A., Scheffer G.L., Scheper R.J., van der Valk P., Baayen J.C., Troost D. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004, 45:441-451.
25. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36:1-6.
26. Dombrowski S.M., Desai S.Y., Marroni M., Cucullo L., Goodrich K., Bingaman W., Mayberg M.R., Bengez L., Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42:1501-1506.
27. Baltes S., Fedrowitz M., Tortos C.L., Potschka H., Loscher W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther. 2007, 320:331-343.
28. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52:333-346.
29. Luna-Tortos C., Fedrowitz M., Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55:1364-1375.
30. Kwan P., Brodie M.J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005, 46:224-235.
31. Stouch T.R., Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev. 2002, 54:315-328.
32. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 1998, 251:252-261.
33. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 2006, 3:3-25.
34. Giessmann T., May K., Modess C., Wegner D., Hecker U., Zschiesche M., Dazert P., Grube M., Schroeder E., Warzok R., Cascorbi I., Kroemer H.K., Siegmund W. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin. Pharmacol. Ther. 2004, 76:192-200.
35. Eyal S., Lamb J.G., Smith-Yockman M., Yagen B., Fibach E., Altschuler Y., White H.S., Bialer M. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br. J. Pharmacol. 2006, 149:250-260.
36. Callen D.F., Baker E., Simmers R.N., Seshadri R., Roninson I.B. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum. Genet. 1987, 77:142-144.
37. Silverman J.A. Multidrug-resistance transporters. Pharm. Biotechnol. 1999, 12:353-386.
38. Borst P. Multidrug resistant proteins. Semin. Cancer Biol. 1997, 8:131-134.
39. Gros P., Croop J., Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986, 47:371-380.
40. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
41. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101:289-294.
42. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:265-269.
43. Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988, 48:1926-1929.
44. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 1990, 38:1277-1287.
45. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:695-698.
46. Beaulieu E., Demeule M., Ghitescu L., Beliveau R. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem. J. 1997, 326(Pt 2):539-544.
47. Lee G., Dallas S., Hong M., Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 2001, 53:569-596.
48. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 1997, 8:161-170.
49. Bendayan R., Lee G., Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc. Res. Tech. 2002, 57:365-380.
50. Demeule M., Regina A., Jodoin J., Laplante A., Dagenais C., Berthelet F., Moghrabi A., Beliveau R. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc. Pharmacol. 2002, 38:339-348.
51. Pardridge W.M., Golden P.L., Kang Y.S., Bickel U. Brain microvascular and astrocyte localization of P-glycoprotein. J. Neurochem. 1997, 68:1278-1285.
52. Schmidt D., Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46:858-877.
53. Begley D.J. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 2004, 10:1295-1312.
54. Kimura Y., Morita S.Y., Matsuo M., Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 2007, 98:1303-1310.
55. Ford J.M., Yang J.M., Hait W.N. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat. Res. 1996, 87:3-38.
56. Ford J.M., Hait W.N. Pharmacologic circumvention of multidrug resistance. Cytotechnology 1993, 12:171-212.
57. Avendano C., Menendez J.C. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Med. Chem. 2002, 9:159-193.
58. Zhang C., Kwan P., Zuo Z., Baum L. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. Life Sci. 2010, 86:899-905.
59. Luna-Tortos C., Rambeck B., Jurgens U.H., Loscher W. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm. Res. 2009, 26:2464-2470.
60. Hung C.C., Chen C.C., Lin C.J., Liou H.H. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet. Genomics 2008, 18:390-402.
61. Kwan P., Baum L., Wong V., Ng P.W., Lui C.H., Sin N.C., Hui A.C., Yu E., Wong L.K. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 2007, 11:112-117.
62. Lazarowski A., Sevlever G., Taratuto A., Massaro M., Rabinowicz A. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr. Neurol. 1999, 21:731-734.
63. Bartmann H., Fuest C., la Fougere C., Xiong G., Just T., Schlichtiger J., Winter P., Boning G., Wangler B., Pekcec A., Soerensen J., Bartenstein P., Cumming P., Potschka H. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010, 51:1780-1790.
64. Brunner M., Langer O., Sunder-Plassmann R., Dobrozemsky G., Muller U., Wadsak W., Krcal A., Karch R., Mannhalter C., Dudczak R., Kletter K., Steiner I., Baumgartner C., Muller M. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin. Pharmacol. Ther. 2005, 78:182-190.
65. Takano A., Kusuhara H., Suhara T., Ieiri I., Morimoto T., Lee Y.J., Maeda J., Ikoma Y., Ito H., Suzuki K., Sugiyama Y. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. J. Nucl. Med. 2006, 47:1427-1433.
66. Volk H.A., Loscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005, 128:1358-1368.
67. Potschka H., Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001, 42:1231-1240.
68. Potschka H., Fedrowitz M., Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001, 12:3557-3560.
69. Potschka H., Fedrowitz M., Loscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett. 2002, 327:173-176.
70. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97:2517-2524.
71. Zhang C., Zuo Z., Kwan P., Baum L. In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011, 52:1894-1904.
72. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., Gottesman M.M. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
73. Chang X.B. A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev. 2007, 26:15-37.
74. Ambudkar S.V., Kim I.W., Sauna Z.E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur. J. Pharm. Sci. 2006, 27:392-400.
75. Leschziner G.D., Andrew T., Pirmohamed M., Johnson M.R. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007, 7:154-179.
76. Frelet A., Klein M. Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett. 2006, 580:1064-1084.
77. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., Dahlin A., Evers R., Fischer V., Hillgren K.M., Hoffmaster K.A., Ishikawa T., Keppler D., Kim R.B., Lee C.A., Niemi M., Polli J.W., Sugiyama Y., Swaan P.W., Ware J.A., Wright S.H., Yee S.W., Zamek-Gliszczynski M.J., Zhang L. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9:215-236.
78. Zhang L., Zhang Y.D., Strong J.M., Reynolds K.S., Huang S.M. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008, 38:709-724.
79. Robey R.W., Lazarowski A., Bates S.E. P-glycoprotein-a clinical target in drug-refractory epilepsy?. Mol. Pharmacol. 2008, 73:1343-1346.
80. Kwan P., Li H.M., Al-Jufairi E., Abdulla R., Gonzales M., Kaye A.H., Szoeke C., Ng H.K., Wong K.S., O'Brien T.J. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol. Dis. 2010, 39:192-197.
81. Sisodiya S.M., Heffernan J., Squier M.V. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999, 10:3437-3441.
82. Jozwiak S. Contemporary opinions on classification, pathogenesis and treatment of drug-resistant epilepsy. Wiad. Lek. 2007, 60:258-264.
83. Marchi N., Hallene K.L., Kight K.M., Cucullo L., Moddel G., Bingaman W., Dini G., Vezzani A., Janigro D. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med. 2004, 2:37.
84. Volk H.A., Burkhardt K., Potschka H., Chen J., Becker A., Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004, 123:751-759.
85. Marchi N., Guiso G., Caccia S., Rizzi M., Gagliardi B., Noe F., Ravizza T., Bassanini S., Chimenti S., Battaglia G., Vezzani A. Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. Neurobiol. Dis. 2006, 24:429-442.
86. Liu X., Yang Z., Yang J., Yang H. Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats. Neuropharmacology 2007, 53:657-663.
87. Seegers U., Potschka H., Loscher W. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res. 2002, 51:257-268.
88. van Vliet E., Aronica E., Redeker S., Marchi N., Rizzi M., Vezzani A., Gorter J. Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res. 2004, 60:203-213.
89. Nishimura A., Honda N., Sugioka N., Takada K., Shibata N. Evaluation of carbamazepine pharmacokinetic profiles in mice with kainic acid-induced acute seizures. Biol. Pharm. Bull. 2008, 31:2302-2308.
90. Seegers U., Potschka H., Loscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 2002, 43:675-684.
91. Xiao Z.Y., Yong, Wang Xuefeng Development of PHT-PB-resistant amygdala-kindled rats and expression of MDR1. Zhonghua Shenjingke Zazhi 1999, 32(6):365-368.
92. Potschka H., Volk H.A., Loscher W. Pharmacoresistance and expression of multidrug transporter P-glycoprotein in kindled rats. Neuroreport 2004, 15:1657-1661.
93. Rizzi M., Caccia S., Guiso G., Richichi C., Gorter J.A., Aronica E., Aliprandi M., Bagnati R., Fanelli R., D'Incalci M., Samanin R., Vezzani A. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J. Neurosci. 2002, 22:5833-5839.
94. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
95. West C.L., Mealey K.L. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. Am. J. Vet. Res. 2007, 68:1106-1110.
96. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
97. Marchi N., Guiso G., Rizzi M., Pirker S., Novak K., Czech T., Baumgartner C., Janigro D., Caccia S., Vezzani A. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 2005, 46:1613-1619.
98. Yang Z.H., Liu X.D. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro. Epilepsy Res. 2008, 78:40-49.
99. Crowe A., Teoh Y.K. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. J. Drug Target 2006, 14:291-300.
100. Owen A., Pirmohamed M., Tettey J.N., Morgan P., Chadwick D., Park B.K. Carbamazepine is not a substrate for P-glycoprotein. Br. J. Clin. Pharmacol. 2001, 51:345-349.
101. Zhang C., Baum L., Zuo Z., Kwan P. Transport of antiepileptic drugs by P-glycoprotein in cell monolayer models. Am. Epilepsy Soc. Ann. Meet. 2009, abst. 2.201.
102. Loscher W., Luna-Tortos C., Romermann K., Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr. Pharm. Des. 2011, 17:2808-2828.
103. Dehouck M.P., Meresse S., Delorme P., Fruchart J.C., Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J. Neurochem. 1990, 54:1798-1801.
104. Cucullo L., Hossain M., Rapp E., Manders T., Marchi N., Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007, 48:505-516.
105. Potschka H., Baltes S., Loscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res. 2004, 58:85-91.
106. Brandt C., Bethmann K., Gastens A.M., Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis. 2006, 24:202-211.
107. van Vliet E.A., van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Wadman W.J., Marchi N., Vezzani A., Gorter J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47:672-680.
108. van Vliet E.A., van Schaik R., Edelbroek P.M., Voskuyl R.A., Redeker S., Aronica E., Wadman W.J., Gorter J.A. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J. Pharmacol. Exp. Ther. 2007, 322:141-147.
109. Sills G.J., Kwan P., Butler E., de Lange E.C., van den Berg D.J., Brodie M.J. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav. 2002, 3:427-432.
110. Yamazaki M., Neway W.E., Ohe T., Chen I., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 2001, 296:723-735.
111. Tang-Wai D.F., Kajiji S., DiCapua F., de Graaf D., Roninson I.B., Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995, 34:32-39.
112. Rambeck B., Jurgens U.H., May T.W., Pannek H.W., Behne F., Ebner A., Gorji A., Straub H., Speckmann E.J., Pohlmann-Eden B., Loscher W. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006, 47:681-694.
113. Langer O., Bauer M., Hammers A., Karch R., Pataraia E., Koepp M.J., Abrahim A., Luurtsema G., Brunner M., Sunder-Plassmann R., Zimprich F., Joukhadar C., Gentzsch S., Dudczak R., Kletter K., Muller M., Baumgartner C. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 2007, 48:1774-1784.
114. Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Discov. Today 2007, 12:833-837.
115. Hoffmann K., Loscher W. Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia 2007, 48:631-645.
116. Ueda K., Taguchi Y., Morishima M. How does P-glycoprotein recognize its substrates?. Semin. Cancer Biol. 1997, 8:151-159.
117. Wen T., Liu Y.C., Yang H.W., Liu H.Y., Liu X.D., Wang G.J., Xie L. Effect of 21-day exposure of phenobarbital, carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain. J. Neurol. Sci. 2008, 270:99-106.
118. Wang Y., Zhou D., Wang B., Li H., Chai H., Zhou Q., Zhang S., Stefan H. A kindling model of pharmacoresistant temporal lobe epilepsy in Sprague-Dawley rats induced by Coriaria lactone and its possible mechanism. Epilepsia 2003, 44:475-488.
119. Wang-Tilz Y., Tilz C., Wang B., Tilz G.P., Stefan H. Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy. Epilepsia 2006, 47:233-239.
120. Seegers U., Potschka H., Loscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur. J. Pharmacol. 2002, 451:149-155.
121. Lu Y., Yan Y., Wang X.F. Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. Chin. Med. J. (Engl) 2004, 117:1682-1686.
122. Yang H.W., Liu H.Y., Liu X., Zhang D.M., Liu Y.C., Liu X.D., Wang G.J., Xie L. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci. Lett. 2008, 434:299-303.
123. Lombardo L., Pellitteri R., Balazy M., Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr. Neurovasc. Res. 2008, 5:82-92.
124. van Vliet E.A., van Schaik R., Edelbroek P.M., da Silva F.H., Wadman W.J., Gorter J.A. Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia 2008, 49:1151-1159.
125. Stables J.P., Bertram E.H., White H.S., Coulter D.A., Dichter M.A., Jacobs M.P., Loscher W., Lowenstein D.H., Moshe S.L., Noebels J.L., Davis M. Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland. Epilepsia 2002, 43:1410-1420.
126. Ak H., Ay B., Tanriverdi T., Sanus G.Z., Is M., Sar M., Oz B., Ozkara C., Ozyurt E., Uzan M. Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure 2007, 16:493-503.
127. Sisodiya S.M., Lin W.R., Harding B.N., Squier M.V., Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125:22-31.
128. Sisodiya S.M., Lin W.R., Squier M.V., Thom M. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001, 357:42-43.
129. Kubota H., Ishihara H., Langmann T., Schmitz G., Stieger B., Wieser H.G., Yonekawa Y., Frei K. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res. 2006, 68:213-228.
130. Lazarowski A., Lubieniecki F., Camarero S., Pomata H., Bartuluchi M., Sevlever G., Taratuto A.L. Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. Pediatr. Neurol. 2004, 30:102-106.
131. Jin R.F., Sun R.P., Xu X.P. Expression of multidrug resistance gene and topiramate affect expression of multidrug resistance gene in the hippocampus of spontaneous epileptic rats. Zhonghua Er Ke Za Zhi 2005, 43:733-737.
132. Maines L.W., Antonetti D.A., Wolpert E.B., Smith C.D. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 2005, 49:610-617.
133. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., Polli J.W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002, 303:1029-1037.